Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Cck-8
2. Cck-op
3. Cholecystokinin Octapeptide
4. Cholecystokinin Pancreozymin C Terminal Octapeptide
5. Cholecystokinin Pancreozymin C-terminal Octapeptide
6. H-asp-tyr(so3h)-met-gly-trp-met-asp-phe-nh2
7. Kinevac
8. Op-cck
9. Sq 19,844
10. Sq 19844
11. Sq-19,844
12. Sq-19844
13. Sq19,844
14. Sq19844
15. Syncalide
1. 25126-32-3
2. Cck-8
3. Kinevac
4. Sq 19844
5. Cck C-terminal Octapeptide
6. Cholecystokinin C-terminal Octapeptide
7. Sq-19844
8. Chembl1121
9. M03giq7z6p
10. Cholecystokinin Octapeptide
11. Caerulein, 1-de(5-oxo-l-proline)-2-de-l-glutamine-5-l-methionine-
12. H-asp-tyr(so3h)-met-gly-trp-met-asp-phe-nh2
13. Cholecystokinin 8
14. Dsstox_cid_28543
15. Dsstox_rid_82815
16. Dsstox_gsid_48617
17. L-aspartyl-l-tyrosyl-l-methionylglycyl-l-tryptophyl-l-methionyl-l-aspartylphenyl-l-alaninamide Hydrogen Sulfate (ester)
18. Sincalidum
19. Sincalida
20. Syncalide
21. (3s,6s,9s,15s,18s,21s)-9-((1h-indol-3-yl)methyl)-21-amino-3-(((s)-1-amino-1-oxo-3-phenylpropan-2-yl)carbamoyl)-6,15-bis(2-(methylthio)ethyl)-5,8,11,14,17,20-hexaoxo-18-(4-(sulfooxy)benzyl)-4,7,10,13,16,19-hexaazatricosanedioic Acid
22. Cas-25126-32-3
23. Human Cck-8
24. Cck-8 (sulphated)
25. Asp-tyr(so3h)-met-gly-trp-met-asp-phe-nh2
26. Sincalidum [inn-latin]
27. Sincalida [inn-spanish]
28. Unii-m03giq7z6p
29. Pancreozymin
30. Sincalide [usan:usp:inn:ban]
31. Ncgc00183278-01
32. Ncgc00183363-01
33. 3-10-caerulein, 5-l-methionine-
34. Einecs 246-639-0
35. Kinevac (tn)
36. Mfcd00079849
37. Sq19844
38. Sincalide [inn]
39. Sincalide [mi]
40. Sincalide (usan/inn)
41. Sincalide [usan]
42. Sincalide [vandf]
43. Cholecystokinin-pancreozymin
44. Sincalide [mart.]
45. Sincalide [who-dd]
46. Cholecystokinin Fragment 26-33 Amide (sulphated)
47. Gtpl864
48. Schembl122365
49. (tyr[so3h]27)cholecystokinin Fragment 26-33 Amide
50. Cck-8(so3)
51. Sincalide [orange Book]
52. Dtxsid7048617
53. Sincalide [usp Impurity]
54. Bdbm21147
55. Chebi:135946
56. (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-oxobutanoic Acid
57. [125i]cck-8
58. 1-de(5-oxo-l-proline)-2-de-l-glutamine-5-l-methioninecaerulein
59. Hy-p0093
60. Sq19844cholecystokinin Octapeptide
61. Tox21_112955
62. Tox21_113481
63. Cholecystokinin Octapeptide, Sulfated
64. Coralynechloridehydrate,98+%
65. Akos016340423
66. Cs-5963
67. Db09142
68. Hs-2026
69. Ncgc00167273-01
70. L-alpha-aspartyl-o-sulfo-l-tyrosyl-l-methionylglycyl-l-tryptophyl-l-methionyl-l-alpha-aspartyl-l-phenylalaninamide
71. Cholecystokinin, Cck Octapeptide (26-33)
72. D05845
73. E78048
74. Asp26-tyr(so3h)-met-gly-trp-met-asp-phenh2
75. 126s323
76. Cholecystokinin C-terminal Octapeptide [mi]
77. Cholecystokinin Octapeptide (sulfated) Ammonium Salt
78. Q7521885
79. (3s)-3-[(2s)-2-[(2s)-2-{2-[(2s)-2-[(2s)-2-[(3s)-3-amino-3-formamidopropanoic Acid]-3-[4-(sulfooxy)phenyl]propanamido]-4-(methylsulfanyl)butanamido]acetamido}-3-(1h-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]-3-{[(1s)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic Acid
80. (3s)-3-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-4-hydroxy-4-oxobutanoyl]amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]acetyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic Acid
81. (3s,6s,9s,15s,18s,21s)-9-((1h-indol-3-yl)methyl)-21-amino-3-(((s)-1-amino-1-oxo-3-phenylpropan-2-yl)carbamoyl)-6,15-bis(2-(methylthio)ethyl)-5,8,11,14,17,20-hexaoxo-18-(4-(sulfooxy)benzyl)-4,7,10,13,16,19-hexaazatricosane-1,23-dioic Acid
82. (3s,6s,9s,15s,18s,21s)-9-((1h-indol-3-yl)methyl)-21-amino-3-((s)-1-amino-1-oxo-3-phenylpropan-2-ylcarbamoyl)-6,15-bis(2-(methylthio)ethyl)-5,8,11,14,17,20-hexaoxo-18-(4-(sulfooxy)benzyl)-4,7,10,13,16,19-hexaazatricosane-1,23-dioic Acid
83. L-.alpha.-aspartyl-o-sulfo-l-tyrosyl-l-methionylglycyl-l-tryptophyl-l-methionyl-l-.alpha.-aspartyl-l-phenylalaninamide
Molecular Weight | 1143.3 g/mol |
---|---|
Molecular Formula | C49H62N10O16S3 |
XLogP3 | -2.6 |
Hydrogen Bond Donor Count | 13 |
Hydrogen Bond Acceptor Count | 19 |
Rotatable Bond Count | 33 |
Exact Mass | 1142.35073945 g/mol |
Monoisotopic Mass | 1142.35073945 g/mol |
Topological Polar Surface Area | 486 Ų |
Heavy Atom Count | 78 |
Formal Charge | 0 |
Complexity | 2180 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 7 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
As the product Kinevac (FDA), sincalide is used for the following indications: 1) to stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals; (2) to stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology; (3) to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract.
FDA Label
V - Various
V04 - Diagnostic agents
V04C - Other diagnostic agents
V04CC - Tests for bile duct patency
V04CC03 - Sincalide
Absorption
The intravenous (bolus) administration of sincalide causes a prompt contraction of the gallbladder that becomes maximal in 5 to 15 minutes, as compared with the stimulus of a fatty meal which causes a progressive contraction that becomes maximal after approximately 40 minutes.
When injected intravenously, sincalide produces a substantial reduction in gallbladder size by causing this organ to contract. The evacuation of bile that results is similar to that which occurs physiologically in response to endogenous cholecystokinin. Like cholecystokinin, sincalide stimulates pancreatic secretion; concurrent administration with secretin increases both the volume of pancreatic secretion and the output of bicarbonate and protein (enzymes) by the gland. This combined effect of secretin and sincalide permits the assessment of specific pancreatic function through measurement and analysis of the duodenal aspirate.
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
39
PharmaCompass offers a list of Sincalide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sincalide manufacturer or Sincalide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sincalide manufacturer or Sincalide supplier.
PharmaCompass also assists you with knowing the Sincalide API Price utilized in the formulation of products. Sincalide API Price is not always fixed or binding as the Sincalide Price is obtained through a variety of data sources. The Sincalide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Cholecystokinin, CCK Octapeptide (26-33) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cholecystokinin, CCK Octapeptide (26-33), including repackagers and relabelers. The FDA regulates Cholecystokinin, CCK Octapeptide (26-33) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cholecystokinin, CCK Octapeptide (26-33) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cholecystokinin, CCK Octapeptide (26-33) manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cholecystokinin, CCK Octapeptide (26-33) supplier is an individual or a company that provides Cholecystokinin, CCK Octapeptide (26-33) active pharmaceutical ingredient (API) or Cholecystokinin, CCK Octapeptide (26-33) finished formulations upon request. The Cholecystokinin, CCK Octapeptide (26-33) suppliers may include Cholecystokinin, CCK Octapeptide (26-33) API manufacturers, exporters, distributors and traders.
click here to find a list of Cholecystokinin, CCK Octapeptide (26-33) suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cholecystokinin, CCK Octapeptide (26-33) DMF (Drug Master File) is a document detailing the whole manufacturing process of Cholecystokinin, CCK Octapeptide (26-33) active pharmaceutical ingredient (API) in detail. Different forms of Cholecystokinin, CCK Octapeptide (26-33) DMFs exist exist since differing nations have different regulations, such as Cholecystokinin, CCK Octapeptide (26-33) USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cholecystokinin, CCK Octapeptide (26-33) DMF submitted to regulatory agencies in the US is known as a USDMF. Cholecystokinin, CCK Octapeptide (26-33) USDMF includes data on Cholecystokinin, CCK Octapeptide (26-33)'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cholecystokinin, CCK Octapeptide (26-33) USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cholecystokinin, CCK Octapeptide (26-33) suppliers with USDMF on PharmaCompass.
A Cholecystokinin, CCK Octapeptide (26-33) written confirmation (Cholecystokinin, CCK Octapeptide (26-33) WC) is an official document issued by a regulatory agency to a Cholecystokinin, CCK Octapeptide (26-33) manufacturer, verifying that the manufacturing facility of a Cholecystokinin, CCK Octapeptide (26-33) active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cholecystokinin, CCK Octapeptide (26-33) APIs or Cholecystokinin, CCK Octapeptide (26-33) finished pharmaceutical products to another nation, regulatory agencies frequently require a Cholecystokinin, CCK Octapeptide (26-33) WC (written confirmation) as part of the regulatory process.
click here to find a list of Cholecystokinin, CCK Octapeptide (26-33) suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cholecystokinin, CCK Octapeptide (26-33) as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cholecystokinin, CCK Octapeptide (26-33) API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cholecystokinin, CCK Octapeptide (26-33) as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cholecystokinin, CCK Octapeptide (26-33) and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cholecystokinin, CCK Octapeptide (26-33) NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cholecystokinin, CCK Octapeptide (26-33) suppliers with NDC on PharmaCompass.
Cholecystokinin, CCK Octapeptide (26-33) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cholecystokinin, CCK Octapeptide (26-33) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cholecystokinin, CCK Octapeptide (26-33) GMP manufacturer or Cholecystokinin, CCK Octapeptide (26-33) GMP API supplier for your needs.
A Cholecystokinin, CCK Octapeptide (26-33) CoA (Certificate of Analysis) is a formal document that attests to Cholecystokinin, CCK Octapeptide (26-33)'s compliance with Cholecystokinin, CCK Octapeptide (26-33) specifications and serves as a tool for batch-level quality control.
Cholecystokinin, CCK Octapeptide (26-33) CoA mostly includes findings from lab analyses of a specific batch. For each Cholecystokinin, CCK Octapeptide (26-33) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cholecystokinin, CCK Octapeptide (26-33) may be tested according to a variety of international standards, such as European Pharmacopoeia (Cholecystokinin, CCK Octapeptide (26-33) EP), Cholecystokinin, CCK Octapeptide (26-33) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cholecystokinin, CCK Octapeptide (26-33) USP).